

Nephros Inc. (NEPH)

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001196298

Nephros Inc. NEPH; healthcare	
Grade	C A B C D E middle fifth of 371 graded peers percentile 43.0; sampling error 2.5 points; lower is stronger
Rank	160 of 371
Profitability	C percentile 49.1
Solvency	C/D percentile 61.6
Growth and financing	B percentile 27.4
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$12.5M to \$120M assets total assets \$13.6M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active; fortress balance sheet not computable: distress
Inputs computable	8 of 14
Graded from	filings received through Apr 30, 2026 162 days before the rescan; latest periodic filing 10-Q received Aug 10, 2026
Last close	\$3.28 2026-10-08; market equity \$35.6M
Price used in grade	None



C, the tortoise
middle fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescan


split-adjusted close; the letter is fixed at the rescan that set it



Rescans on file: D from Apr 21, 2023, C from Mar 21, 2024, D from Apr 21, 2025

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 12, 2026

is a commercial-stage company that develops and markets high-performance water filtration solutions for points of use, with a core focus on medical-grade water filtration. Our medical filtration portfolio includes two product lines: infection control and dialysis water. The infection control segment features both microfilters (0.1 micron), which retain bacteria, and ultrafilters (0.005 micron), which retain bacteria, viruses, and endotoxins to address a broader spectrum of waterborne pathogens including and beyond

Legionella and Pseudomonas.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 49.1						
Gross profitability		85.2%	32.2%	6.7	372	2025-12-31
Return on invested capital		not computable	9.3%			required facts have no common fiscal period end
Accruals ratio		(3.6%)	(6.6%)	68.3	811	2025-12-31
Gross margin stability, five years		5.4 pts	2.8 pts	72.3	243	2025-12-31
Solvency, sleeve percentile 61.6						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(26.46)	(0.31)	78.4	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000 interest expense must exceed \$100,000
Interest coverage		not computable	(4.51x)			
Current ratio		4.06x	2.96x	44.7	839	2025-12-31
Growth and financing, sleeve percentile 27.4						
Revenue growth, three-year compound		23.5%	10.0%	28.0	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000 pretax income must exceed the validity floor and imply a 0%-100% tax rate
Reinvestment rate		not computable	37.1%			
Asset growth, three years		7.4%	2.1%	36.1	704	2025-12-31
Net share issuance, one year		0.4%	2.5%	18.0	634	2026-03-12


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 3,563,000 USD; Altman Z is not used

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
155	Envista Holdings Corp. (NVST)	41.6	B/C	
156	Xeris Biopharma Holdings, Inc. (XERS)	41.9	B/C	
157	Sight Sciences, Inc. (SGHT)	42.2	B/C	fortress
				balance sheet
158	Community Health Systems Inc. (CYH)	42.4	B/C	
159	Ligand Pharmaceuticals Inc. (LGND)	42.7	C	
160	Nephros Inc. (NEPH) <	43.0	C	fortress
				balance sheet
161	Immucell Corp. (ICCC)	43.2	C	
162	Innoviva, Inc. (INVA)	43.5	C	
163	Addus HomeCare Corp. (ADUS)	43.8	C	
164	NovoCure Ltd. (NVCR)	44.1	C	fortress
				balance sheet
165	Medtronic plc (MDT)	44.3	C	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(9.5%)	8.0%	40
Distance from 52-week high	(43.1%)	(31.4%)	35
EBIT to enterprise value	3.7%	(1.5%)	71
Free cash flow yield	(1.5%)	(1.0%)	48
Book value to price	0.33	0.28	56
Sales to price	0.53	0.31	67
Composite equity issuance, five years	9.1%	20.3%	39
Relative strength against the sector, log excess return	(0.31)	(0.14)	40

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$4.7M
Operating cash flow, four quarters	-\$661,000
Months of runway	85.3

Days since last periodic filing

60 (10-Q received Aug 10, 2026)

Median daily dollar volume, 63 sessions

\$71,211

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$11.6M	2025-12-31	2026-03-12	10-K	0001493152-26-009848
2	assets	us-gaap:Assets	\$13.6M	2025-12-31	2026-03-12	10-K	0001493152-26-009848
3	net income	us-gaap:NetIncomeLoss	\$1.2M	2025-12-31	2026-03-12	10-K	0001493152-26-009848
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$1.6M	2025-12-31	2026-03-12	10-K	0001493152-26-009848
5	assets	us-gaap:Assets	\$11.2M	2024-12-31	2026-03-12	10-K	0001493152-26-009848
6	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$18.8M	2025-12-31	2026-03-12	10-K	0001493152-26-009848
7	gross profit	us-gaap:GrossProfit	\$8.7M	2024-12-31	2026-03-12	10-K	0001493152-26-009848
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$14.2M	2024-12-31	2026-03-12	10-K	0001493152-26-009848
9	gross profit	us-gaap:GrossProfit	\$8.4M	2023-12-31	2025-03-24	10-K	0001641172-25-000234
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$14.2M	2023-12-31	2025-03-24	10-K	0001641172-25-000234
11	gross profit	us-gaap:GrossProfit	\$4.7M	2022-12-31	2024-03-15	10-K	0001493152-24-010107
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$10.0M	2022-12-31	2024-03-15	10-K	0001493152-24-010107
13	gross profit	us-gaap:GrossProfit	\$5.6M	2021-12-31	2023-03-23	10-K	0001493152-23-008716
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$10.2M	2021-12-31	2023-03-23	10-K	0001493152-23-008716
15	current assets	us-gaap:AssetsCurrent	\$11.2M	2025-12-31	2026-03-12	10-K	0001493152-26-009848
16	current liabilities	us-gaap:LiabilitiesCurrent	\$2.8M	2025-12-31	2026-03-12	10-K	0001493152-26-009848
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$143.1M	2025-12-31	2026-03-12	10-K	0001493152-26-009848
18	operating income	us-gaap:OperatingIncomeLoss	\$1.1M	2025-12-31	2026-03-12	10-K	0001493152-26-009848
19	book equity	us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterests	\$10.2M	2025-12-31	2026-03-12	10-K	0001493152-26-009848
20	liabilities	us-gaap:Liabilities	\$3.4M	2025-12-31	2026-03-12	10-K	0001493152-26-009848
21	total debt	us-gaap:LongTermDebt	\$71,000	2022-12-31	2023-03-23	10-K	0001493152-23-008716
22	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$3.6M	2022-12-31	2024-03-15	10-K	0001493152-24-010107
23	operating income	us-gaap:OperatingIncomeLoss	-\$4.3M	2022-12-31	2024-03-15	10-K	0001493152-24-010107
24	depreciation amortization	us-gaap:Depreciation	\$93,000	2022-12-31	2024-03-15	10-K	0001493152-24-010107
25	operating income	us-gaap:OperatingIncomeLoss	-\$1.6M	2023-12-31	2025-03-24	10-K	0001641172-25-000234
26	interest expense	us-gaap:InterestExpense	\$2,000	2023-12-31	2024-03-15	10-K	0001493152-24-010107
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$492,000	2024-12-31	2026-03-12	10-K	0001493152-26-009848
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$55,000	2024-12-31	2026-03-12	10-K	0001493152-26-009848
29	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$827,000	2023-12-31	2025-03-24	10-K	0001641172-25-000234
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$75,000	2023-12-31	2025-03-24	10-K	0001641172-25-000234
31	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$3.2M	2022-12-31	2024-03-15	10-K	0001493152-24-010107
32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$137,000	2022-12-31	2024-03-15	10-K	0001493152-24-010107
33	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$1.4M	2021-12-31	2023-03-23	10-K	0001493152-23-008716
34	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$36,000	2021-12-31	2023-03-23	10-K	0001493152-23-008716
35	depreciation amortization	us-gaap:Depreciation	\$46,000	2024-12-31	2026-03-12	10-K	0001493152-26-009848
36	operating income	us-gaap:OperatingIncomeLoss	\$6,000	2024-12-31	2026-03-12	10-K	0001493152-26-009848
37	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$19,000	2023-12-31	2026-03-12	10-K	0001493152-26-009848
38	income tax	us-gaap:IncomeTaxExpenseBenefit	\$15,000	2024-12-31	2026-03-12	10-K	0001493152-26-009848
39	current assets	us-gaap:AssetsCurrent	\$8.3M	2024-12-31	2026-03-12	10-K	0001493152-26-009848
40	current liabilities	us-gaap:LiabilitiesCurrent	\$1.6M	2024-12-31	2026-03-12	10-K	0001493152-26-009848
41	current assets	us-gaap:AssetsCurrent	\$8.4M	2023-12-31	2025-03-24	10-K	0001641172-25-000234
42	current liabilities	us-gaap:LiabilitiesCurrent	\$2.1M	2023-12-31	2025-03-24	10-K	0001641172-25-000234
43	assets	us-gaap:Assets	\$11.9M	2023-12-31	2025-03-24	10-K	0001641172-25-000234
44	assets	us-gaap:Assets	\$11.0M	2022-12-31	2024-03-15	10-K	0001493152-24-010107
45	shares outstanding	dei:EntityCommonStockSharesOutstanding	10,644,268	2026-03-12	2026-04-30	10-K/A	0001493152-26-020416
46	shares outstanding	dei:EntityCommonStockSharesOutstanding	10,600,350	2025-03-17	2025-03-24	10-K	0001641172-25-000234